Form 4: Lisata Therapeutics CEO David Mazzo Reports Stock Transactions

David Mazzo, CEO of Lisata Therapeutics, reports acquisition and disposal of common stock due to vesting of performance-based stock units and tax liability coverage.

Summary

• On October 1, 2024, David J. Mazzo, the President & CEO of Lisata Therapeutics, acquired 58,000 shares of common stock at a price of $2.93 per share due to the vesting of performance-based stock units.
• On the same day, Mazzo disposed of 26,964 shares of common stock at $2.93 per share to cover tax liabilities associated with the vesting of the performance-based stock units.
• Following these transactions, Mazzo directly owns 211,834 shares of Lisata Therapeutics common stock, which includes 107,183 unvested restricted stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are related to standard compensation practices and tax obligations. There is no indication of unusual or concerning activity.

Positives

• The vesting of performance-based stock units suggests that performance criteria were met, which could be viewed positively.

Negatives

• The disposal of shares to cover tax liabilities could be seen as a slight negative, although it's a common practice.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates transactions related to compensation and tax obligations, which are typical occurrences.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they primarily reflect internal compensation adjustments.

Key Dates